Medical University of South Carolina

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1955-01-01

Employees: 10K

Market Cap: -

Website: https://www.muschealth.com

Clinical Trials

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

Phase 2

Completed

Conditions: Marijuana Abuse
Mood Disorders

First Posted Date: 2005-09-08

Last Posted Date: 2015-10-09

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 81

Registration Number: NCT00149617

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Magnetic Brain Stimulation for the Treatment of Adult Depression

Phase 2

Completed

Conditions: Depression

Interventions: Procedure: Prefrontal rTMS
Drug: Antidepressant Regimen
Procedure: Sham Stimulation

First Posted Date: 2005-09-08

Last Posted Date: 2018-12-28

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 190

Registration Number: NCT00149838

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Brain Stimulation Laboratory, Medical University of South Carolina, Charleston, South Carolina, United States

and more 1 locations

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-07-11

Last Posted Date: 2018-05-11

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 1

Registration Number: NCT00118196

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Velcade
Drug: LH-RH Agonist
Drug: Androgen Receptor Antagonists

First Posted Date: 2005-02-08

Last Posted Date: 2018-11-05

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 23

Registration Number: NCT00103376

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

and more 1 locations

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: docetaxel
Drug: GnRh analog
Radiation: radiotherapy

First Posted Date: 2004-12-09

Last Posted Date: 2024-01-31

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 20

Registration Number: NCT00099086

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

First Posted Date: 2004-11-09

Last Posted Date: 2018-04-10

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 36

Registration Number: NCT00096304

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-09-13

Last Posted Date: 2018-05-16

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 49

Registration Number: NCT00003344

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Biological: PEG-interferon alfa-2b
Biological: GM-CSF
Drug: thalidomide

First Posted Date: 2004-09-08

Last Posted Date: 2018-07-12

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 10

Registration Number: NCT00090870

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-08-05

Last Posted Date: 2018-07-16

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 9

Registration Number: NCT00089102

Locations: 🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-08-05

Last Posted Date: 2018-07-12

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 16

Registration Number: NCT00089128

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy